Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 40Leukemia, Myeloid, Acute 24Congenital Abnormalities 22Leukemia, Lymphocytic, Chronic, B-Cell 16Breast Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 14Lymphoma, Mantle-Cell 12Myelodysplastic Syndromes 11Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Leukemia, Megakaryoblastic, Acute 10Myeloproliferative Disorders 9Lymphoma 9Leukemia, Monocytic, Acute 9Leukemia, Erythroblastic, Acute 9Burkitt Lymphoma 9Lymphoma, Large-Cell, Immunoblastic 8Leukemia, Myelomonocytic, Chronic 8Leukemia, Myelomonocytic, Acute 8Leukemia, Myeloid, Chronic-Phase 8Waldenstrom Macroglobulinemia 7Sezary Syndrome 7Neoplastic Cells, Circulating 7Mycosis Fungoides 7Melanoma 7Lymphoma, T-Cell, Cutaneous 7Lung Neoplasms 7

Interventions

Dexamethasone 27Melphalan 22Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 14Filgrastim 13Bortezomib 12Calcium Dobesilate 9Lenalidomide 7fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Cyclosporine 5Thalidomide 4Interferon-alpha 4Etoposide 4Busulfan 4miridesap 3dexamethasone acetate 3Radiotherapy 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Carboplatin 3pomalidomide 2liposomal amphotericin B 2ixazomib 2daratumumab 2birtamimab 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoglobulin Light-chain Amyloidosis × Flow Cytometry × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡